

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

DISCLOSEABLE TRANSACTION PROPOSED ACQUISITION OF INTEREST IN KPC PROGRESS UPDATE

Reference is made to the announcement of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 10 May 2022 (the “**Announcement**”) in relation to the proposed acquisition of interest in KPC Pharmaceuticals, Inc (昆藥集團股份有限公司)(“**KPC**”). Unless otherwise defined herein or the context requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

PROGRESS OF THE PROPOSED ACQUISITION

The Board is pleased to announce that China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (華潤三九醫藥股份有限公司)(“**CR Sanjiu**”) has received the approval letter (forwarded by China Resources Company Limited) dated 21 December 2022 issued by the State-owned Assets Supervision and Administration Commission of the State Council (the “**SASAC**”) (Guo Zi Chan Quan [2022] No. 586), pursuant to which, the SASAC, among other things, granted an approval in-principle to CR Sanjiu to acquire the controlling interest in KPC by CR Sanjiu’s acquisition of 3,335,456 shares of KPC from Holley Group Company Limited (華立集團股份有限公司) and 208,976,160 shares of KPC from Holley Pharmaceutical Group Co., Ltd. (華立醫藥集團有限公司).

As disclosed in the Announcement, the Proposed Acquisition by CR Sanjiu under the Share Purchase Agreement is subject to the fulfilment of certain conditions precedent, including the shareholders' approval of the Proposed Acquisition at a general meeting of CR Sanjiu. As at the date of this announcement, the Proposed Acquisition has not been completed. The Company will make further announcement(s) with respect to the progress of the Proposed Acquisition as and when necessary and appropriate.

Shareholders and potential investors should note that the Proposed Acquisition contemplated under the Share Purchase Agreement are subject to the fulfilment of the conditions precedent stated thereunder and may or may not proceed. Accordingly, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 23 December 2022

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.